Modification of the inhibitory amino acid for epitope peptide binding onto major histocompatibility complex class II molecules enhances immunogenicity of the antigen.
D000595:Amino Acid Sequence; D000818:Animals; D000917:Antibody Formation / Q000276:immunology; D000918:Antibody Specificity; D001120:Arginine / Q000276:immunology; D002455:Cell Division / Q000276:immunology; D018984:Epitopes, T-Lymphocyte / Q000378:metabolism; D000949:Histocompatibility Antigens Class II / Q000276:immunology*; D008213:Lymphocyte Activation / Q000276:immunology; D013058:Mass Spectrometry; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D008969:Molecular Sequence Data; D009113:Muramidase / Q000235:genetics / Q000276:immunology* / Q000494:pharmacology; D016297:Mutagenesis, Site-Directed; D010446:Peptide Fragments / Q000235:genetics / Q000276:immunology* / Q000494:pharmacology; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology / Q000494:pharmacology; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology*
D018984:Epitopes, T-Lymphocyte; D000949:Histocompatibility Antigens Class II; D010446:Peptide Fragments; D011994:Recombinant Proteins; C066759:hen egg lysozyme peptide (46-61); D001120:Arginine; D009113:Muramidase